Risk of Vertebral Compression Fractures in Long-term Survivors After Stereotactic Radiosurgery for Spine Metastases

Corresponding author: Diane Ling

1. Rad Onc, UPMC CancerCenter 2. Department of Radiation Oncology, University of Pittsburgh Medical Center 3. Department of Neurosurgery, University of Pittsburgh Medical Center 4. Department of Radiation Oncology, UPMC Hillman Cancer Center 5. Department of Neurological Surgery, University of Pittsburgh Medical Center 6. Neurosurgery, University of Pittsburgh Medical Center 7. Radiation Oncology, University Of Pittsburgh 8. Neurosurgery, University of Pittsburgh Medical Center 9. Radiation Oncology, West Virginia University

Categories: Neurosurgery, Radiation Oncology
Keywords: stereotactic radiosurgery, srs

Abstract

Objectives: Vertebral compression fracture (VCF) is potentially disabling sequelae of spine radiation therapy. The reported risk of VCF following stereotactic radiosurgery (SRS) for the primary treatment or re-irradiation of spinal metastases ranges from 6-39%, although follow-up in most series is limited to 1-2 years. Our aim was to document the 5- and 10-year incidence of vertebral compression fracture in long-term survivors following SRS for spine metastases.

Methods: A single-institution retrospective review was completed on 562 patients treated with SRS for spine metastases between April 2001 and July 2011. Selecting those with a minimum of 5-year survival after SRS resulted in 43 patients who collectively underwent 84 treatments at 51 spine sites. The incidence of de novo VCF or progression of pre-existing VCFs occurring in the absence of tumor progression was recorded. Binary logistic regression was used to identify potential predictors VCF. The Kaplan-Meier method was used to analyze the actuarial rate of VCF.

Results: Median follow-up per treatment site was 81 months (range: 60-133). Most were treated with single-fraction SRS to a median dose of 16 Gy (range: 12-24), and 31 (61%) sites had been treated with prior external beam radiation therapy to a median total biologic equivalent dose (BED3) of 60 Gy (range: 27-131) with a median re-irradiation interval of 12.3 months (range: 0.9-145). Nine (18%) lesions were managed with kyphoplasty for a pre-existing pathologic fracture prior to SRS. Of 51 sites treated, a total of 9 (17.6%) vertebral compression fractures occurred at a median time of 18 months (range: 3-57 months), with 5- and 10-year VCF rates of 16% and 16%, respectively. Seven (78%) vertebral compression fractures occurred de novo, and 2 (22%) were progression of a pre-existing fracture. Eight fractures (89%) were symptomatic with pain, and 5 (56%) required surgical stabilization with kyphoplasty (n=4) or posterior spinal fusion (n=1). Age, gender, primary tumor type, sclerotic vs. lytic lesion type, presence of pre-existing compression fracture, SRS dose, cumulative BED of all prior treatments, and gross tumor volume did not predict subsequent vertebral compression fracture.

Conclusions: SRS for the primary treatment or re-irradiation of spinal metastases is associated with a moderate risk of VCF up to 5 years following treatment, with a plateau in incidence thereafter up to 10 years. No predictors for late development of VCF were identified.